Surface Fn14 is used as a target for the delivery of immunotoxins and antibody‐drug conjugates to reduce the number of Fn14‐expressing tumor cells (Zhou et al, 2013, 2014; Lerchen et al, 2018; Alvarez de Cienfuegos et al, 2020; Dancy et al, 2020). This evidence concerns the gene TNFRSF12A and neoplasm.